AMLX

Amylyx Pharmaceuticals, Inc. AMLX

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,731 of 2,753

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$2.07B total
FMR LLC
$300.43M+0.6%
BlackRock, Inc.
$158.53M0.0%
PERCEPTIVE ADVISORS LLC
$149.69M+0.6%
TCG Crossover Management, LLC
$112.14M0.0%
Commodore Capital LP
$101.47M0.0%
Jupiter Topco LLC
$94.01M--
Saturn V Capital Management LP
$83.05M+6.3%
VANGUARD CAPITAL MANAGEMENT LLC
$75.87M+2.0%
MORGAN STANLEY
$56.23M+43.9%
DRIEHAUS CAPITAL MANAGEMENT LLC
$54.54M+1.7%
First Light Asset Management, LLC
$54.30M-5.2%
FRANKLIN RESOURCES INC
$52.99M+30.5%
GOLDMAN SACHS GROUP INC
$51.33M+8.8%
STATE STREET CORP
$46.76M+10.2%
GEODE CAPITAL MANAGEMENT, LLC
$41.95M+5.6%
JPMORGAN CHASE & CO
$34.92M+1067.2%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$34.12M-46.6%
Siren, L.L.C.
$26.59M+20.4%
EVENTIDE ASSET MANAGEMENT, LLC
$23.84M-12.3%
683 Capital Management, LLC
$22.98M-16.4%
VANGUARD PORTFOLIO MANAGEMENT LLC
$19.07M+12.4%
Alyeska Investment Group, L.P.
$18.91MNew
Almitas Capital LLC
$17.51M-54.1%
DIMENSIONAL FUND ADVISORS LP
$16.22M-0.1%
Jones Hill Capital LP
$16.06M-44.1%
See all 207 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AMLX

Earnings Per Share

13fpro.ai/company/AMLX

Loading ratio trend…

AMLX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Amylyx Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Amylyx Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$87.4M$-301.7M—
FY 2023$380.8M$49.3M10.2%
FY 2022$22.2M$-198.4M—
FY 2021$285.0K$-87.9M—
Source: AMLX filings on SEC EDGAR →

AMLX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in AMLX

1 transaction in AMLX reported by 1 member of Congress under the STOCK Act, most recent trade Oct 12, 2022. Reported transactions, not recommendations.

All Congress stock trades →

About Amylyx Pharmaceuticals, Inc. (AMLX): stock profile, AI score and financials

Amylyx Pharmaceuticals, Inc. (AMLX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMLX at 8.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,731 of 2,753 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.3) and revenue growth (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AMLX by reported 13-F value include FMR, BlackRock, PERCEPTIVE ADVISORS, based on the most recent SEC filings. AMLX trades on the Nasdaq exchange and files with the SEC under CIK 1658551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amylyx Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1658551 →